Europe Epilepsy Drugs Market Forecast to 2030 - Regional Analysis - by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others)

The Europe epilepsy drugs market was valued at US$1.94 billion in 2022 and is expected to reach US$2.62 billion by 2030; it is estimated to grow at a CAGR of 3.8% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Europe Epilepsy Drugs Market

Epilepsy is one of the prevalent neurological disorders affecting the geriatric population. According to the National Center for Biotechnology Information, epilepsy is the third most common neurological disorder affecting the elderly after dementia and stroke. The incidence of epilepsy is increasing in older adults, partly because of the growing prevalence of stroke, brain tumors, and dementia. Considering that modern society is aging, the overall prevalence and incidence of epilepsy are expected to rise.

The Eurostat statistics indicate that over one-fifth (21.1%) of the European population was aged 65 or more in 2022. According to an article published by UpToDate Inc. in August 2021, the incidence rate of epilepsy rises with age and is highest among patients aged 75 and above.

Therefore, due to the growing geriatric population, there is notable surge in conditions such as epilepsy owing to which the market for epilepsy drugs witnesses a significant growth.

Europe Epilepsy Drugs Market Overview

The Europe epilepsy drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy drugs market. The European epilepsy drugs market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Drugs Market Segmentation

The Europe epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Europe epilepsy drugs market is segmented Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the Europe epilepsy drugs market.